about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

New Jer­sey's bait worked: Af­ter promise of $40M in in­cen­tives, Te­va is mov­ing its HQ

7 years ago
Pharma

Trump in­vites phar­ma heads to pri­vate din­ner dur­ing Lon­don vis­it, a trip that's in­spir­ing tens of thou­sands to ...

7 years ago
People
Pharma

FDA OKs Xeomin in fourth in­di­ca­tion; Nextbi­otix rais­es $8M for mi­cro­bio­me tech

7 years ago
News Briefing

THC ther­a­py tanks in PhI, send­ing Zyner­ba's stock tum­bling yet again

7 years ago
R&D

Mer­ck scores pri­or­i­ty re­view Keytru­da in squa­mous NSCLC; Syn­thet­ic Ge­nomics spin­out SGI-DNA gets new CEO

7 years ago
News Briefing

Is Mar­tin Shkre­li blog­ging from prison?

7 years ago
People

Sanofi gets se­ri­ous in Chi­na with plans to hire 300 for $76M R&D site in Cheng­du

7 years ago
R&D
China

No­var­tis to spin off Al­con eye care unit, buy back $5B in stock; Ri­val CAR-Ts from No­var­tis and Gilead get thumbs up ...

7 years ago
News Briefing

Ac­ne was a bust, but ex­ces­sive sweat­ing scores FDA OK for Der­mi­ra — shares climb

7 years ago
Pharma

Fi­nal­ly, Cel­gene wins. Ane­mia drug lus­pa­ter­cept — part­nered with Ac­celeron — scores in PhI­II tri­al

7 years ago
R&D

Ama­zon snaps up on­line phar­ma­cy start­up Pill­Pack in lat­est move to dis­rupt health­care

7 years ago
Deals

Tout­ing PhI­II suc­cess for arthri­tis drug Taltz, Eli Lil­ly chas­es ri­val No­var­tis in heat­ed im­munol­o­gy race

7 years ago
R&D

Meet Jen­nifer Pet­ter: Boston start­up Ar­rakis cel­e­brates a big per­son­al tran­si­tion for top ex­ec

7 years ago
People

CAR macrophage tu­mor tech cre­at­ed by UPenn star sci­en­tists gets $53M

7 years ago
Financing
Startups

Roivant un­der­goes ma­jor re­struc­tur­ing, cut­ting and shift­ing its staff

7 years ago
Startups
R&D

Achao­gen hits, then miss­es: FDA OKs Zem­dri for cUTIs, but re­jects sec­ond in­di­ca­tion

7 years ago
Pharma

De­men­tia Dis­cov­ery Fund clos­es $350M, re­cruits Cel­gene ex­ec as CEO; Ex-Lazard banker Ian Woo joins C-Bridge and ...

7 years ago
News Briefing

Food-sourced mi­cro­bio­me drugs get $101M megaround for Flag­ship's Kalei­do

7 years ago
Financing
Startups

Af­ter Ro­va-T bust, Ab­b­Vie plans new sol­id tu­mor as­sault, li­cens­ing next-gen CAR-T tech from Cal­i­br

7 years ago
R&D
Discovery

A slim­mer FDA: White House pro­pos­es 30% cut to head­count un­der re­or­ga­ni­za­tion

7 years ago
Pharma

On a win­ning streak, Heron rock­ets up 30% on PhI­Ib pain drug da­ta

7 years ago
R&D

No­vo takes on gut-brain ax­is dis­cov­ery with Kally­ope, fo­cus­ing on obe­si­ty and di­a­betes

7 years ago
R&D
Pharma

Build­ing up its rare obe­si­ty pipeline, Rhythm Phar­ma to raise $150M

7 years ago
R&D

Re­plac­ing lab rats? Bay Area tech fund backs Em­u­late's $36M round to com­mer­cial­ize 'or­gan chip' tech

7 years ago
Financing
Discovery
First page Previous page 1234567 Next page Last page
A service from the Financial Times